A detailed history of Kbc Group Nv transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Kbc Group Nv holds 2,039 shares of BEAM stock, worth $51,566. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,039
Previous 2,039 -0.0%
Holding current value
$51,566
Previous $48,000 4.17%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

BUY
$21.22 - $32.66 $5,177 - $7,969
244 Added 13.59%
2,039 $48,000
Q4 2023

Feb 13, 2024

BUY
$17.69 - $30.76 $31,753 - $55,214
1,795 New
1,795 $49,000
Q3 2023

Feb 15, 2024

SELL
$23.01 - $32.46 $14,266 - $20,125
-620 Reduced 34.54%
1,175 $28,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.